il-1β converting enzyme

Ossirene (AS101), a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta converting enzyme.

SDZ 224-015 is an orally active inhibitor of interleukin-1β (IL-1β) converting enzyme and caspase-1, exhibiting anti-COVID-19 and anti-inflammatory activity, and reducing carrageenan gum-induced paw edema in rats.

Boc-Asp(OBzl)-CMK, an inhibitor of IL-1 converting enzyme (ICE, caspase1), prevents the death of CHP100 neuroblastoma cells and inhibits IL-1β release induced by the viral coat protein [1].

Dabcyl YVADAPV EDANS is a fluorescent IL-1β converting enzyme (ICE) substrate that can be used to detect ICE-like protease activity. Dabcyl YVADAPV EDANS detects fluorescence at λex=360 nm, λem=480 nm.

Ac-YVAD-CHO (L-709049) acetate is a potent, reversible, and specific tetrapeptide interleukin-1β converting enzyme (ICE) inhibitor, also demonstrating specificity for caspase-1. It exhibits K_i values of 3.0 nM in mice and 0.76 nM in humans, underscoring its efficacy. Additionally, Ac-YVAD-CHO acetate inhibits the production of mature IL-1β, highlighting its therapeutic potential [1] [2] [3].

Ac-YVAD-CHO (L 709049) is a selective and potent tetrapeptide interleukin 1β-converting enzyme (ICE) and caspase-1 (ICE)-like protease inhibitor with anti-inflammatory activity, inhibits cancer cell growth, and inhibits the production of mature IL-lβ. Ac-YVAD-CHO attenuates quinolinic acid-induced p53 increase and apoptosis in rat striatum.

Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan is an effective, non-peptide, and orally active interleukin-1β converting enzyme inhibitor (Ki: 1.4 nM). Pralnacasan has the potential for osteoarthritis and rheumatoid a